

For Immediate Release:

June 3, 2009

Contact:

Mary Kuramoto

513-579-9911 X 2523

m.kuramoto@medpace.com**Medpace Inc. takes the top spot as the best CRO for Overall Working Relationship as rated by U.S. Investigative Sites in CenterWatch, 2009 Site Survey**

CINCINNATI, OH (June 3, 2009) — Medpace, a global full-service clinical research organization today announced it has been named the 2009 Top [Clinical Research Organization \(CRO\)](#) by CenterWatch, a highly regarded trade publication for the clinical development industry. The rating is the result of a 2009 industry-wide U.S. investigator site survey. The site survey was administered to 22,500 investigative sites across the country with 950 responding. In total, 11 CROs were named in the 2009 study. Medpace was rated the number one CRO with 82% of sites rating Medpace as “Good” and “Excellent” for overall relationship quality. A ten percentage point differential separated Medpace from the number two CRO industry finalist.

Medpace was selected as the number one CRO by scoring highly across 29 key relationship attributes. The most important attributes as determined by sites were: Monitor and Clinical Research Associate (CRA) professionalism and training, [project management](#), protocol design, study initiation, and responsiveness to queries.

“It’s an honor to be supported by critical partners of our sites, I think it’s a reflection of the close relationship that we have with sites with which we work. Our success is dependent upon them and we do our best to support them,” said Medpace President and CEO, August Troendle, M.D. Strategic partnering with Sponsors is a key strength of the company. Clinical Development partnerships are inclusive of investigator sites as well.

Staff professionalism was the number one ranked attribute by the sites. Medpace was rated as “Excellent” in this attribute by 58% of the sites, achieving the top position by a differential of 17 percentage points over the second best rated CRO. Troendle attributed this rating to a lower than average turnover rate for Medpace CRAs and a centrally based monitoring system located at the Medpace global headquarters in Cincinnati.

“A relationship can only be built with some sort of continuity, and I think our turnover rate of 5% for CRAs, which is less than half what the competition has, I think that’s an important factor,” Dr. Troendle said. “Part of that is our central model. Most of the industry has gone to a regionally based support model for CRAs—for monitors. ... regional CRAs don’t have as much interest in the company; they don’t really see it as part of their team—their family.”

Other key factors for which Medpace ranked the highest included a 60% “Excellent” rating in organization and preparedness and a 46% “Excellent” rating in protocol design. “This acknowledgement from sites is particularly an honor because of the effort Medpace places on hiring expertise at all levels of the organization. Medpace hires top [Medical and Regulatory](#) talent to write clinical development plans and protocols that both satisfy the regulatory requirements while being doable, safe and ethical for the investigative sites and their patients. We thank our sites for recognizing this effort,” said Dr. Jonathan Isaacsohn, VP of Medical and Regulatory Affairs.

CenterWatch has conducted the biannual site survey since 1997. The survey is developed with input from industry Sponsors. CenterWatch is considered a leading publication delivering current clinical development news and trends for the clinical trials industry.

Medpace has experienced tremendous growth over the past two years with 1000 employees and revenue of \$143 million in 2008. Medpace has expanded its global base of business and has added full services including the Medpace Clinical Pharmacology Unit and the Medpace Bioanalytical Laboratories in 2009.

###

ABOUT MEDPACE

Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused team to execute at every level of the company's operations, providing complete and seamless drug development services.

Through specialized regulatory expertise and therapeutically focused clinical operations, Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development – from program planning and execution to product approval.

With 1000 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, [central laboratories](#), and therapeutically specialized testing from Medpace Reference Laboratories, complete [bioanalytical services](#) in all stages of drug development from Medpace Bioanalytical Laboratories, and central image management and reading from Imagepace.

Visit the Medpace website at www.medpace.com.